SUBLINGUAL FORMULATION OF RILUZOLE

(19)

(11)

EP 3 616 686 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	23.06.2021 Bulletin 2021/25

(45)	Mention of the grant of the patent:
	19.05.2021 Bulletin 2021/20

(21)	Application number: 19186196.2

(22)	Date of filing: 17.11.2015

(51)

International Patent Classification (IPC):

A61K 9/00^(2006.01)
A61K 9/20^(2006.01)
A61K 47/20^(2006.01)
A61P 25/00^(2006.01)
A61P 25/18^(2006.01)
A61P 25/24^(2006.01)
A61P 25/30^(2006.01)

A61K 31/428^(2006.01)
A61K 9/08^(2006.01)
A61K 47/26^(2006.01)
A61P 25/16^(2006.01)
A61P 25/22^(2006.01)
A61P 25/28^(2006.01)

(54)	SUBLINGUAL FORMULATION OF RILUZOLE SUBLINGUALE FORMULIERUNG VON RILUZOL FORMULATION SUBLINGUALE DE RILUZOLE

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

21.11.2014 US 201462083094 P

(43)	Date of publication of application:
	04.03.2020 Bulletin 2020/10

(60)	Divisional application:
	21169884.0

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	15823415.3 / 3220891

(73)	Proprietor: Biohaven Pharmaceutical Holding Company Ltd.
	New Haven, CT 06520 (US)

(72)	Inventors:
	CORIC, Vladimir Madison, CT 06443 (US) BERMAN, Robert, M. New Haven, CT 06511 (US) VLADYKA, Ronald, Samuel Somerst NJ 08873 (US) SALEH, Amgad Dayton NJ 08810 (US) YU, Danny Somerville MA 08876 (US)

(74)	Representative: Mewburn Ellis LLP
	Aurora Building Counterslip Bristol BS1 6BX Bristol BS1 6BX (GB)

(56)

References cited: :

WO-A2-2013/010015
US-A1- 2014 371 277

CA-A1- 2 864 008

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).